



## **ORGANISATION - COMMITTEES**

#### ORGANISATION

ISBT Executive Committee (2004-2006)

Francine Décary, President Shigeru Takamoto, President-elect Yong Ming Zhu, Vice-President Mahmut Bayik Vice-President Hans Erik Heier, Past-President Geoffrey Lane, Treasurer Paul Strengers, Secretary-General

#### ISBT Board of Directors (2004-2006)

Yasmin Ayob
Celso Bianco
Judith Chapman
Magdelena Letowska
Maria Cristina Martinez
Faten Moftah
Rachanee O'Charoen
Diana Teo
Graham M. Thurtell

#### **Local Organising Committee**

Congress President
Secretary
Alice Maniatis
Olga Marantic
Dimitris Lilis
Members
John Christakis

Alice Maniatis
Olga Marantidou
Dimitris Lilis
John Christakis
Effi Economou
Savas Sourmelis
Ioanna Spiliotopoulou
Kostas Vagianos

## CONGRESS ORGANISATION

Congress Organiser

(General and scientific programme, registration, sponsoring, exhibition)

#### **Eurocongres Conference Management**

Jan van Goyenkade 11

1075 HP Amsterdam, The Netherlands

Tel.: +31 20 679 3411 Fax: +31 20 673 7306

E-mail: isbt.athens@eurocongres.com

## Local Congress Organiser / Official Travel Agency

(Hotel accommodation, social programme, travel, accompanying persons and local exhibition)

#### **ERA Ltd**

8, Alex. Soutsou Street

106 61 Kolonaki, Athens, Greece

Tel.: +30 210 363 4944 Fax: +30 210 363 1690 E-mail: info@era.gr.

# CONGRESS COMMITTEES SCIENTIFIC COMMITTEE

#### Chairman

Irene Kontopoulou-Griva, Greece

#### **Honorary Members**

Titika Mandalaki, Greece Nitsa Renieri, Greece

#### Members

Svetla Bakalova, Bulaaria Mahmut Bayik, Turkey Loukas Dadiotis, Greece Aikaterini Egglezou, Greece Valentina Hafner, Romania Tor Hervig, Norway Anastasia Karafoulidou, Greece Marina Karakazta, Greece Harvey Klein, USA Jukka Koistinen, Finland Garyfalia Kokkini, Greece Volker Kretchmer, Germany Despina Kyriakou, Greece Stavroula Lacoumenta, Greece Magdalena Letowska, Poland Anna Manitsa, Greece Brian Mc Clelland, United Kingdom Athanasia Mouzaki, Greece William Murphy, Ireland George Palatianos, Greece Myrsiny Parara, Greece Konstantina Politi, Greece Philippe Rouger, France Kyriaki Sofroniadou, Greece Paul Strengers, the Netherlands Eleni Theodori, Greece George Theodosiadis, Greece Anthi Travlou, Greece Claudio Velati, Italy Miguel Angel Vesga Cara, Spain Lenka Walterova, Czech Rep. Eleftheria Zervou, Greece

#### **Local Advisory Committee**

Demetrios Ablianitis
Emmanouil Anastassiou
Antonia Dimakopoulou
Elisabeth Grouzi
Helen Hassapopoulou
Kyriaki Hatzidimitriou
Kalliopi Louizou
Afroditi Loutradi
Kostas Markakis
George Martinis
Kostas Stamoulis
Regina Stathopoulou
Vassilis Tsevrenis

# INTERNATIONAL SOCIETY OF BLOOD TRANSFUSION ATINA, JULY 2-6, 2005

PREVENTION OF POSTTRANSFUSION REACTIONS WITH USE OF LEUCOREDUCED ERYTROCYTE CONCENTRATES IN THERAPY OF SECONDARY ANAEMIA IN PATIENTS WITH MALIGNANT DISEASE Vitlarova J., Kamcev N., Jankulovska S., Cuckova B., Kamceva M.

WU Transfusiology, Medical Center - Stip, Macedonia

**Background:** The presence of leucocytes in blood components is cause for apperance of various adverse postranfusion reactious such as NHFPTRs, urticary, anaphylactic shock, alloimunization and platelet refractorines, infection with bacteria and leucothropyc viruses (CMV, HTLV). The removal of leucocytes from blood components through filtration is especially important in the treatment of patients with malignant diseases who need frequent transfusions of blood and blood components. This is because of their lowered immunologic status which is a result of the disease and recived immunosupresive chemoterapy and radiotherapy.

**Aim:** To show the prevention of postransfusion reactions and the positive effect from transfusion of leucoreduced Er. Concentrates, produced with filtration in therapy of anaemia in patients with malignant diseases, treated in our Daily transfusion hospital at Medical center – Stip.

**Methods:** 123 patients with malignant diseases have been treated in our Daily transfusion hospital in the last four years. Most of these patients suffer from Ca pulmonum, Ca collonis, Ca uteri, Ca mammae. Also, because of the secondary anaemia, the same patients were transfunded with at least two doses of leucoreduced Er. concentrates. The blood donored by voluntary repeated blood donors was filtrated the same day after the donation, separation and the control of the same one. The blood was collected in Baxter and Terumo bags, and it was filtrated with Baxter – Sepacell RS – 2000 and Pall – purecell RN filters. The analyses of leucoreduction were made for every filtrated and transfunded unit before and after filtration. The analyses samples were taken from the tubing sistem before and after the filter. Haemathologic parameters were automaticaly made in the Central Clinic Laboratory.

**Results:** Er. concentrates poor with the leucocytes for about 98-99.9% were produced with the use of these filters, and platelets from 88-100% with which side effects from frequent transfusious at these patients were prevented. With the routine monitoring of all patients none postransfusion reactions were registered. The therapeutic effect is also important because of the fact that the number of Er and the level of Hg and Hct remain almost unchanged.

Couclusion: The aim of the Blood banks is to help and to increase the safety of the blood components. The leucoreduction through of Er. concentrates poor with leucocytes is a regular procedure in the therapy of malignant patients with remarkable clinical picture of anaemic syndrom and prevention the cancer reccurence end infection. The time of filtration is also very imortant which has to be shorter after collection of blood, because the leucocytes should be removed before they become desintegrated and relase potentially dangerous substances end metabolites in the blood components. We have been applying so called "prestorage filtration" because it hase been proved that it is more efficient that bed – side filtration.